Sun Acquisitions

AUGUST 22, 2024

By integrating complementary businesses and resources, M&A can help companies secure more reliable supply chains and ensure consistent product availability. Securing Reliable Supply Chains through M&A Diversification of Supply Sources A primary strategy to manage product shortages is diversifying supply sources.

M&A 52

M&A Management Mergers and Acquisitions Food 52

Devensoft

AUGUST 24, 2023

Mastering Operations, Cross-Selling, and Cost Efficiencies for Maximizing Value from Integrated Ventures The Power of Synergy and Value Creation Amidst the dynamic and fiercely competitive modern business arena, corporations continually strive to secure a distinct market advantage while fostering expansion.

Business 52

Business Collaboration Mergers and Acquisitions Management 52

Cooley M&A

JANUARY 25, 2023

But it wasn’t all carve outs and concerned investors – even with the headwinds in the industry and beyond, there were still several traditional public M&A deals involving biotechnology or medical device companies, as large pharmaceutical companies continued to have cash to deploy for acquisitions.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Devensoft

AUGUST 22, 2023

Similarly, when companies from different geographic regions aim to collaborate, freelance modeling can cater to the complexities of cross-cultural integration. Consider a merger between a pharmaceutical company and a biotech startup. Conventional integration plans might have been rigid, focusing solely on aligning technical systems.

M&A 52

M&A Business Mergers and Acquisitions Collaboration 52

Cooley M&A

JANUARY 23, 2024

While the year saw an overall decline in M&A activity (down 17% from 2022) , total pharmaceuticals and life sciences deal value in 2023 increased by approximately 50% compared to 2022. Collaborate or buy?’ Why did life sciences outperform the market? The last quarter of the year ended with a surge of deal activity.

M&A 52

M&A Mergers and Acquisitions Acquisitions Pharmaceutical 52

Cooley M&A

JANUARY 22, 2020

A wave of big-ticket transactions by global pharmaceutical companies drove life sciences M&A activity to its fourth-largest year on record in 2019, with aggregate deal value in the pharmaceutical, medical and biotech industry reaching $234.2 2019 was a banner year for billion-dollar life sciences M&A transactions.

M&A 40

M&A Pharmaceutical Acquisitions Capital 40

Software Equity Group

JANUARY 22, 2024

A shift to patient-centered care A growing body of research and consumer demand are pushing healthcare organizations to adopt a more personalized, collaborative, comprehensive approach to caring for patients’ whole-health needs. It enables interoperability between clinical, administrative and financial systems, and makes data more secure.

Healthcare 52

Healthcare M&A Valuation Medical 52